Fibrocell Science, Inc. to Host Investor Conference Call to Discuss Business Update

EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on commercializing LAVIV, the first and only FDA-approved personalized cell therapy in aesthetic dermatology, and on developing innovative autologous cell therapies for additional aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will host an investor conference call to discuss Fibrocell’s private placement financing and strategic collaboration with Intrexon Corporation on Wednesday, October 17, 2012 at 4:30 PM Eastern Time.